Rhee, Soo-Yon, Margeridon-Thermet, Severine, Nguyen, Mindie H., Liu, Tommy F., Kagan, Ron M., Beggel, Bastian, Verheyen, Jens, Kaiser, Rolf and Shafer, Robert W. (2010). Hepatitis B virus reverse transcriptase sequence variant database for sequence analysis and mutation discovery. Antiviral Res., 88 (3). S. 269 - 276. AMSTERDAM: ELSEVIER. ISSN 1872-9096

Full text not available from this repository.

Abstract

Drug resistance resulting from reverse transcriptase (RI) mutations is one of the main obstacles to successful hepatitis B virus (HBV) therapy. Indeed, HBV treatment guidelines recommend HBV genotypic resistance testing for patients receiving nucleos(t)ide RT inhibitors (N(t)RTIs) who develop virological failure. N(t)RTI-resistance mutations at 10 RT positions have been well characterized in phenotypic studies, however, data are lacking on the relative frequency of these mutations in N(t)RTI-treated and untreated individuals. There are also few published data on the extent of amino acid variation at most of the 344 positions of HBV RI and the extent to which this variation is influenced by N(t)RTI treatment. We retrieved 23,871 HBV RI sequences from GenBank and reviewed the published reports of these sequences to ascertain the number of individuals from whom the sequences were obtained, the N(t)RTI treatments of these individuals, and the year and region of virus sampling. We then used these data to populate a relational database we named HBVrtDB. As of July 2010, HBVrtDB contained 6811 sequences from 3869 individuals reported in 281 references. Among these 3869 individuals, 73% were N(t)RTI-naive and 27% received one or more N(t)RTIs. Among the 10 well-characterized N(t)RTI-resistance mutations, L80I/V, V173L, L180M, A181T, T184S, S202G and M204I/V were significantly assocated with treatment with lamivudine, an L-nucleoside analog, and A181S/T/V and N236T were significantly associated with treatment with adefovir, an acyclic nucleoside phosphonate. A similar analysis of ten additional less well-characterized resistance mutations demonstrated a significant association with N(t)RTI treatment for four of the mutations: L82M, S85A, A200V, and Q215S. We also created an interactive program, HBVseq, to enable users to identify mutations in submitted sequences and retrieve the prevalence of these mutations in HBVrtDB according to genotype and N(t)RTI treatment. HBVrtDB and HBVseq are available at http://hivdb.stanford.edu/HBV/releaseNotes/. (C) 2010 Elsevier B.V. All rights reserved.

Item Type: Journal Article
Creators:
CreatorsEmailORCIDORCID Put Code
Rhee, Soo-YonUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Margeridon-Thermet, SeverineUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Nguyen, Mindie H.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Liu, Tommy F.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Kagan, Ron M.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Beggel, BastianUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Verheyen, JensUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Kaiser, RolfUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Shafer, Robert W.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
URN: urn:nbn:de:hbz:38-491119
DOI: 10.1016/j.antiviral.2010.09.012
Journal or Publication Title: Antiviral Res.
Volume: 88
Number: 3
Page Range: S. 269 - 276
Date: 2010
Publisher: ELSEVIER
Place of Publication: AMSTERDAM
ISSN: 1872-9096
Language: English
Faculty: Unspecified
Divisions: Unspecified
Subjects: no entry
Uncontrolled Keywords:
KeywordsLanguage
RESISTANCE; POLYMERASE; HBVMultiple languages
Pharmacology & Pharmacy; VirologyMultiple languages
URI: http://kups.ub.uni-koeln.de/id/eprint/49111

Downloads

Downloads per month over past year

Altmetric

Export

Actions (login required)

View Item View Item